Joe's Big IdeaJoe's Big Idea is a new project by NPR Science Correspondent Joe Palca that examines where scientists' big ideas come from, how they pursue those ideas and how something goes from an idea to a discovery.
Joe's Big Idea
Exploring how ideas become innovations and inventions
President Trump announced in May that he was taking hydroxychloroquine as a preventive measure against COVID-19. But a study published Wednesday finds no evidence the drug is protective in this way.
GEORGE FREY/AFP via Getty Images
TRACE field staff assemble nasal swabs, collection tubes and other materials into home sampling kits. All field staff are tested for COVID-19 each week prior to working.
Laura de la Torre/Oregon State University
Footage issued by Britain's Oxford University shows a person injected as part of human trials in the U.K. to test a potential coronavirus vaccine last month. Pfizer on Monday began U.S. trials of another vaccine candidate.
Oxford University Pool via AP
Mammoth Biosciences and researchers at the University of California, San Francisco are working on a coronavirus test that could run multiple samples at once, with results in 35-40 minutes. Even better, they say, it doesn't require the sophisticated, expensive equipment used in other tests for the virus.
Regeneron Pharmaceuticals, headquartered near Tarrytown, N.Y., is just one of the companies now working to identify and reproduce large quantities of antibodies that could prevent or treat COVID-19. Senior R&D Specialist Kristen Pascal works on COVID-19 research for Regeneron.
Rani Levy/Regeneron Pharmaceuticals
Pharmacist Raphael Lynne gives a flu shot in Miami in 2018. This year's vaccination against influenza has been reducing infections by "about 40 to 50 percent," says Emily Martin, an epidemiologist with the University of Michigan School of Public Health.
Joe Raedle/Getty Images